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Abstract
The prognosis of patients affected by
myelofibrosis (MF) is usually dismal and
allogeneic hematopoietic stem cell trans-
plantation (HSCT) remains the only cure.
The number of HSCTs in MF patients has
recently increased. However, a major obsta-
cle is still represented by primary graft fail-
ure (PGF). Currently there are no definitive
guidelines for the treatment of PGF and a
second HSCT can be performed only when
an allogeneic donor is rapidly available.
Herein we report on a MF patient with PGF
after an unrelated HSCT, who was rescued
by a non-myeloablative, unmanipulated,
haploidentical HSCT that resulted in per-
sistent engraftment and bone-marrow fibro-
sis regression, but not in a long-term disease
control. Based on this experience we briefly
review the role of different conditioning
regimens and hematopoietic stem cell
sources in the setting of HSCT for MF
patients with PGF. The role of haploidenti-
cal donors in MF patients lacking HLA-
matched relatives is also discussed.
Introduction
Myelofibrosis (MF) is a pathological
condition caused by the clonal proliferation
of a pluripotent stem cell. It is characterized
by a deregulated kinase signaling, and an
abnormal release of cytokines, the latter
being responsible for the induction of bone-
marrow (BM) fibrosis.1 MF is associated
with three main driver mutations namely
the V617F mutation of the Janus Kinase 2
(JAK2) gene (in ~60% of cases), and muta-
tions of the calreticulin (CARL) and the
myeloproliferative leukemia protein (MPL)
genes (in ~30% and 8% of cases, respec-
tively).1,2 MF can arise de novo as primary
myelofibrosis (PMF) or following essential
thrombocythemia or polycythemia vera.
Clinical presentation of MF includes blood
cytopenia, leukoerithroblastosis,
extramedullary hematopoiesis, progressive
splenomegaly, and systemic symptoms.3 In
spite of the recent developments of targeted
therapies (e.g., JAK1/2 inhibitors), the
prognosis of MF patients is usually dismal
and the allogeneic hematopoietic stem cell
transplantation (HSCT) remains the only
cure.3 Improvements in patient selection,
conditioning strategies and timing, have
recently contributed to increase the number
of HSCTs in MF patients.4 However, one of
the major obstacles for a successful HSCT
is represented by primary graft failure
(PGF), which has been reported in 2% to
25% of MF patients.1
PGF is caused by the absence of an ini-
tial cell donor engraftment and is defined as
the persistence of severe neutropenia
together with red blood cells and platelets
transfusion dependence after the HSCT
conditioning. It is associated with a consid-
erable morbidity and mortality, mainly driv-
en by severe infections. A number of factors
contribute to PGF, including hematopoietic
stem cell (HSC) source, conditioning regi-
men, HLA disparity, AB0 mismatches, and
infections.5 In myeloproliferative neo-
plasms possible causes of PGF may also
include a defective BM stroma, splenic con-
sumption of infused HSCs and allo-immu-
nization following multiple transfusions.5
In MF patients increased levels of plasma
cytokines (mostly TNF-α) may also exert a
cytotoxic activity against HSCs.1
Worthy of note BM fibrosis has not
been clearly proven to correlate with PGF,
but rather a consequence of an altered
cytokine milieu able to reverse upon the
replacement of the abnormal hematopoietic
system.6 In the absence of definitive guide-
lines for the treatment of PGF patients may
undergo a second HSCT, which can be per-
formed using the same or another allogene-
ic donor when available.
Case Report
A 54-year-old woman was referred to
our Institution on December 2012 with
painful splenomegaly and systemic symp-
toms. Blood tests showed leukocytosis
(24×109/L) and thrombocytopenia
(97×109/L). The circulating CD34+ cells
were 2.4%. The BM aspirate was not evalu-
able due to the poor cellularity, while the
BM biopsy was consistent with PMF. The
karyotype was normal and the molecular
analysis revealed the presence of the JAK2
V617F mutation. The patient was diagnosed
with an intermediate-1 PMF according to
the International Prognostic Scoring
System.7 She was first treated with hydrox-
yurea, then with ruxolitinib, which became
available in our Institution starting from
February 2013. In spite of an initial reduc-
tion of the spleen size and the remission of
the systemic symptoms, on May 2014 rux-
olitinib was withdrawn due to the reappear-
ance of both painful splenomegaly and sys-
temic symptoms, and the patient underwent
splenectomy followed by treatment with
hydroxyurea. 
Although the Dynamic International
Prognostic Scoring System (DIPSS) score
was now intermediate-2,8 the HSCT was
not performed because the only patient’s
brother was HLA haploidentical and no
unrelated donors were unavailable. A few
months later, a 10/12 matched male donor
(antigen mismatch in DPB1) was identified
and a peripheral blood hematopoietic stem
cell (PBSC) HSCT could be scheduled.
Patient and donor differed in AB blood
group systems and CMV serostatus (B+ vs
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A+, CMV IgG positive vs negative). The
BM biopsy done before the HSCT was
revealing that the patient’s BM had a diffuse
and intense fibrosis (Figure 1).9 At that time
the DIPSS score was still intermediate-2,
and the HSCT-comorbidity index was
low.10 The HSCT was finally administered
on March 2015 with a myeloablative condi-
tioning consisting of busulfan (16 mg/kg
i.v.) and cyclophosphamide (120 mg/kg
i.v.). The patient received 10.66×106/kg
CD34+ cells, while the CD3+ cells infused
were 24.47×106/kg. Graft-versus-host dis-
ease (GVHD) prophylaxis included rabbit
antithymocyte globulins, cyclosporine and
short course methotrexate. In spite of the
high number of CD34+ cells infused, on
day +28 the patient was diagnosed with
PGF. At that time an empirical antibacterial
and antimycotic therapy was being deliv-
ered due to a persistent fever and the CT-
scan evidence of a single excavated lesion
of 5-6 cm on the upper lobe of the left lung
in the absence of galactomannan positivity.
The urgent requirement for a new donor
and the rapid worsening of the patient’s
clinical condition (ECOG3) prompted us to
schedule as a salvage treatment a PBSC
HSCT from the haploidentical brother, who
was AB0-mismatched (A+) and CMV IgG
positive. Therefore, on day +37 from the
first HSCT, the patient received 6×106/kg
CD34+ and 32.6×107/kg CD3+ cells from
the brother, following a conditioning regi-
men consisting of only fludarabine (30
mg/m2 day for 3 days). On day +3 after the
haploidentical HSCT the patient underwent
cyclophosphamide (50 mg/kg i.v.) and start-
ing from day +4 cyclosporine and
mycophenolate mofetil as GVHD prophy-
laxis. G-CSF was given from day +5 and it
was stopped on day +13, when the engraft-
ment was documented. Starting from the
same time the patient presented a grade II
skin GVHD that required steroid therapy
until day +49. Following the haploidentical
HSCT, the BM aspirate was performed on
day +21, +90, and +180, showing a full-
donor chimerism by either fluorescence in
situ hybridization with sex chromosome-
specific DNA probes, and variable number
tandem repeats analysis. Worthy of note, the
BM biopsies performed on day +90 and
+180 showed a progressive reduction of
BM fibrosis as shown in Figure 1.
Importantly, the excavated lesion of the
left lung was progressively decreasing and
no GVHD was observed.
Unfortunately, on day +290 a relapse of
disease was documented and the patient
died of pulmonary infection few months
later while in palliative treatment.
Discussion
The immediate availability of new
donors for patients experiencing PGF is of
critical importance and in this perspective
the use of related haploidentical donors may
offer obvious advantages. However, the
new conditioning regimen together with the
increased immunosuppression required to
overcoming HLA disparity, may cause
severe organ toxicities and infections.
Recent reports have shown that haploidenti-
cal HSCT, either T-cell depleted,11,12 or
unmanipulated,13-17 usually preceded by
reduced intensity conditioning (RIC), can
be safely and effectively administered to
patients with PGF. However, the patients
described in the aforementioned reports
were mainly affected by acute or chronic
myeloid leukemia, juvenile myelomonocyt-
ic leukemia, or myelodisplastic syn-
drome.11-17
To the best of our knowledge, the suc-
cessful administration of unmanipulated
haploidentical HSCTs has been previously
described only in two MF patients with a
follow-up of 30 and 11.5 months respec-
tively, who had reported a PGF after an
unrelated HLA full-matched RIC-HSCT.14
In both cases the 1-day conditioning regi-
men was composed of 30 mg/m2 fludara-
bine, 2 g/m2 cyclophosphamide, 20 mg
alemtuzumab i.v., and 200 cGy total body
irradiation, based on the assumption that the
first preparative regimen might had already
suppressed the recipient’s immune systems.
As for our patient, the conditioning scheme
initially scheduled,18 actually included only
fludarabine (30 mg/m2 for 3 days) given the
poor patient’s clinical status and the lack of
any residual hematopoiesis at the BM biop-
sy of day +28 (not shown). Moreover, in
contrast to the original schedule,18 we
infused PBSCs instead of BM, due to the
need of a rapid engraftment. Interestingly,
in agreement with a recent study demon-
strating a better outcome for PGF patients
receiving PBMCs as compared to other
stem cell sources,19 most of the PGF
patients who underwent a haploidentical
HSCT also received PBMCs.13-17
Worthy of note, in our patient the
engraftment paralleled the progressive
regression of BM fibrosis (Figure 1), there-
fore confirming previous experiences evi-
dencing that a high fibrosis grading is not a
major obstacle to HSCT in MF patients, but
instead a dynamic process largely depend-
ent on the microenvironment.6
As for our patient, the haploidentical
HSCT was able to overcome the PGF and to
reduce the BM fibrosis. However it turned
out to be ineffective against the long-term
control of the disease, thus suggesting that
the conditioning regimen delivered and/or
the transplant-related immune-mediated
effect, were not capable of eradicating the
disease.
Conclusions
Overall, given the limits of a single
experience, this clinical case indicates that
the unmanipulated haploidentical HSCT
may be effective in rescuing MF patients
from PGF. In addition, the higher number of
PGF observed in patients undergoing unre-
lated HSCT,19 together with the difficulties
of delivering a new conditioning regimen,
support recent data indicating that the hap-
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Figure 1. Grading of bone-marrow fibrosis (MF) according to the WHO guidelines using the Gomori stain. MF was evaluated: A)
before the unrelated allogeneic HSCT, B) before the haploidentical HSCT, C) on day +90 and D) on day +180 following the hap-
loidentical HSCT. Final magnification 200×.
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loidentical donor may be a reasonable first
option for MF patients lacking a HLA-
matched relative.20 We are aware that only
prospective studies aimed at comparing the
outcome of recipients of conventional ver-
sus alternative donors will definitively
establish the role of haploidentical HSCT in
MF patients.
References
1. Cervantes F. How I treat myelofibrosis.
Blood 2014;124:2635-42.
2. Tefferi A, Vannucchi AM. Genetic risk
assessment in myeloproliferative neo-
plasms. Mayo Clin Proc 2017;92:1283-
90.
3. Gupta V, Gotlib J, Radich JP, et al. Janus
kinase inhibitors and allogeneic stem
cell transplantation for myelofibrosis.
Biol Blood Marrow Transplant
2014;20:1274-81.
4. Kroger NM, Deeg JH, Olavarria E, et al.
Indication and management of allogene-
ic stem cell transplantation in primary
myelofibrosis: a consensus process by
an EBMT/ELN international working
group. Leukemia 2015;29: 2126-33.
5. Olsson RF, Logan BR, Chaudhury S, et
al. Primary graft failure after myeloabla-
tive allogeneic hematopoietic cell trans-
plantation for hematologic malignan-
cies. Leukemia 2015;29:1754-62.
6. Kroger N, Kvasnicka M, Thiele J.
Replacement of hematopoietic system
by allogeneic stem cell transplantation
in myelofibrosis patients induces rapid
regression of bone marrow fibrosis.
Fibrogenesis Tissue Repair 2012;5:S25.
7. Cervantes F, Dupriez B, Pereira A, et al.
New prognostic scoring system for pri-
mary myelofibrosis based on a study of
the International Working Group for
Myelofibrosis Research and Treatment.
Blood 2009;113:2895-901.
8. Passamonti F, Cervantes F, Vannucchi
AM, et al. A dynamic prognostic model
to predict survival in primary myelofi-
brosis: a study by the IWG-MRT
(International Working Group for
Myeloproliferative Neoplasms Research
and Treatment). Blood 2010;115:1703-
8.
9. Thiele J, Kvasnicka HM, Facchetti F, et
al. European consensus on grading bone
marrow fibrosis and assessment of cel-
lularity. Haematologica 2005;90:1128-
32.
10. Sorror ML, Maris MB, Storb R, et al.
Hematopoietic cell transplantation
(HCT)-specific comorbidity index: a
new tool for risk assessment before allo-
geneic HCT. Blood 2005;106:2912-9.
11. Moscardo F, Romero S, Sanz J, et al. T
cell-depleted related HLA-mismatched
peripheral blood stem cell transplanta-
tion as salvage therapy for graft failure
after single unit unrelated donor umbili-
cal cord blood transplantation. Biol
Blood Marrow Transplant
2014;20:1060-3.
12. Park JA, Koh KN, Choi ES, et al.
Successful rescue of early graft failure
in pediatric patients using T-cell-deplet-
ed haploidentical hematopoietic SCT.
Bone Marrow Transplant 2013;49:270-
5.
13. Yoshihara S, Ikegame K, Taniguchi K,
et al. Salvage haploidentical transplanta-
tion for graft failure using reduced-
intensity conditioning. Bone Marrow
Transplant 2011;47:369-73.
14. Kanda J, Horwitz ME, Long GD, et al.
Outcomes of a 1-day non myeloablative
salvage regimen for patients with pri-
mary graft failure after allogeneic
hematopoietic cell transplantation. Bone
Marrow Transplant 2012;47:700-5.
15. Tang BL, Zhu XY, Zheng CC, et al.
Successful early unmanipulated hap-
loidentical transplantation with reduced-
intensity conditioning for primary graft
failure after cord blood transplantation
in hematologic malignancy patients.
Bone Marrow Transplant 2015;50:248-
52.
16. Perini GF, Kerbauy FR, Fernandes JF, et
al. Haploidentical non-myeloablative
stem cell transplantation as salvage for
graft failure in a patient with juvenile
myelomonocytic leukemia. Pediatr
Blood Cancer 2011;57:1084.
17. Pagliuca S, Legendre H, Morin S, et al.
Success of haploidentical hematopoiet-
ic stem cells transplantation in the treat-
ment of graft failure. Ann Hematol
2016;95:353-4.
18. Luznik L, O’Donnell PV, Symons HJ, et
al. HLA-haploidentical bone marrow
transplantation for hematologic malig-
nancies using non myeloablative condi-
tioning and high-dose, post transplanta-
tion cyclophosphamide. Biol Blood
Marrow Transplant 2008;14:641-50.
19. Fuji S, Nakamura F, Hatanaka K, et al.
Peripheral blood as a preferable source
of stem cells for salvage transplantation
in patients with graft failure after cord
blood transplantation: a retrospective
analysis of the registry data of the
Japanese Society for Hematopoietic
Cell Transplantation. Biol Blood
Marrow Transplant 2012;18:1407-14.
20. Bregante S, Dominietto A, Ghiso A, et
al. Improved outcome of alternative
donor transplantations in patients with
myelofibrosis: from unrelated to hap-
loidentical family donors. Biol Blood
Marrow Transplant 2016;22:324-9.
                             Case Report
